Chronic lymphocytic leukaemia (CLL) is the most common form of leukaemia in the Western World. B-cell receptor-induced intracellular signals are critical for the survival of leukaemia cells and disruption of this pathway by the Bruton’s tyrosine kinase (Btk) inhibitor ibrutinib is a highly effective CLL therapy. However, ibrutinib treatment is associated with adverse bleeding due to the inhibition of Btk and Tec kinases in platelets. Ibrutinib is also associated with an increased risk of infections.
The aim of this project is to investigate the role of Btk and Btk inhibitors on the role of platelets as innate immune effectors in CLL utilising samples from healthy donors and a large well-characterised cohort of CLL patients.
This project will involve studying the effect of Btk inhibitors on platelet aggregatory, trans-migratory and adhesive responses to bacteria and Btk inhibitors. The role of Btk in modulating platelet cytokine release responses and inflammasome responses will also be investigated. The student will also investigate cell signalling responses using flow cytometry and immunoblotting techniques.
This is a full time PhD in Medical Sciences.
For informal inquiries, please contact Dr. Monica Arman ([email protected]
Location and Research Culture
Hull York Medical School’s unique partnership brings together the expertise of both the Universities of Hull and York and offers a thriving environment in which to conduct world-leading research. Strong partnerships with NHS Trusts and community health organisations offer a wide clinical base within which to study those conditions which most affect our communities – improving their health while developing research work that can be applied nationally and globally.
The School’s academic and clinical researchers at have a strong reputation for their work, 85% of which is classed as ‘world-leading’ or ‘internationally excellent’ (REF 2014). Their research is advancing improvements in healthcare – treatment, diagnosis and care – improving the health of people locally and impacting national and international health agendas. http://www.hyms.ac.uk
The student will join a dynamic research team and thriving community of graduate students from the UK and overseas in the Centre for Atherothrombosis and Metabolic Disease at the University of Hull. Many students also study in our laboratories at local hospitals across the city. This gives our students unparalleled access to the facilities, academic and clinical expertise to thrive in their research.
Dr. Monica Arman, Lecturer in Biomedical Science, Centre for Atherothrombosis and Metabolic Disease.
Email: [email protected]
To be arranged upon acceptance of an offer.
In order to qualify for this position, you will require an undergraduate degree with at least a 2.1, or equivalent, in a relevant subject (Biochemistry, Molecular and Cellular Biology, Pharmacology, Pharmacy or related discipline). English Language IELTS 6.5 with a minimum of 6.0 in each component.
How to Apply
All applications MUST be submitted through the HYMS Postgraduate Centre via the online application system: https://www.york.ac.uk/study/postgraduate/courses/apply?course=DRPMEDSMED3&level=postgraduate
Please apply for a “PhD in Medical Sciences” at Hull York Medical School. Please quote HYMS with the project title when applying. In order for the Panel to get a sense of your academic background, commitment and interest, you are required to complete the application form in full and provide a research proposal/outline of academic interest. Research proposals and personal statements may be used in selecting applicants for interview. If you have any queries on how to apply, please email [email protected]
Applicants who are shortlisted for interview will be sent details of the date, time and venue via email. If you are not invited for interview, it means that your application has not been successful. Please note that we do not offer feedback to applicants who are not invited to the interview.